Valo Health Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities

<p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><img src="https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/image_92706a9ee1.png" alt="PatSnap MCP servers used for the Valo Health BD opportunity scan"></a></p><p><strong>This Valo Health Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows.</strong> Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP tests for recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. <a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener">Explore the MCP servers used in this report.</a></p><p><em>Decision date: 22 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply a usable record and must not be read as evidence of absence.</em></p><h2>Executive BD thesis</h2><p>Valo Health is screened as a potential partnering counterparty across asset licensing, regional commercialization, co-development, platform access and evidence-generation structures. The organization pipeline call returned 22 records at the decision date. The lead returned asset is <strong>OPAL-0012</strong>, associated with USP7 and Non-Small Cell Lung Cancer, at Preclinical. The immediate objective is to identify a narrow, executable right set and the evidence package required to test strategic fit.</p><p>A high-quality first meeting should confirm the current development owner, decision rights, territory availability, stage definitions, program status, patent ownership, third-party licenses, CMC readiness, clinical evidence, regulatory history and management’s preferred transaction structure. Pipeline size is a starting signal, not a substitute for strategic fit or diligence.</p><h2>Partnering shortlist</h2><table><thead><tr><th>Priority</th><th>Asset / workstream</th><th>Owner</th><th>Stage</th><th>Evidence package</th><th>IP risk screen</th><th>Deal precedent</th><th>Outreach rationale</th></tr></thead><tbody><tr><td>1</td><td><strong>OPAL-0012</strong></td><td>Valo Health LLC</td><td>Preclinical</td><td>Pipeline record: USP7; Non-Small Cell Lung Cancer. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Valo Health Announces Collaboration with Merck KGaA, Darmstadt, Germany to Discover and Develop Novel Treatments for Parkinson’s Disease and Related Disorders</td><td>Preclinical asset with USP7 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>2</td><td><strong>OPL-0101</strong></td><td>Valo Health LLC</td><td>Preclinical</td><td>Pipeline record: IL-2R x NKG2D; Locally Advanced Melanoma. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Valo Health and nference Announce Long-term Partnership to Accelerate Human-Centric Drug Discovery and Development</td><td>Preclinical asset with IL-2R x NKG2D exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>3</td><td><strong>Lupus(Valo Health)</strong></td><td>Valo Health LLC</td><td>Preclinical</td><td>Pipeline record: target not returned; Lupus Erythematosus. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Novo Nordisk Adds Obesity and Diabetes to AI Drug Research Pact With Flagship’s Valo Health</td><td>Preclinical asset with target not returned exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>4</td><td><strong>WO2023239789</strong></td><td>Valo Health, Inc.</td><td>Discovery</td><td>Pipeline record: PARP; B-Cell Malignant Neoplasm, Neoplasms. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Valo Health Announces Collaboration with Merck KGaA, Darmstadt, Germany to Discover and Develop Novel Treatments for Parkinson’s Disease and Related Disorders</td><td>Discovery asset with PARP exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>5</td><td><strong>WO2024261710</strong></td><td>Valo Health, Inc.</td><td>Discovery</td><td>Pipeline record: PARP x PARP1 x PARP2; B-Cell Malignant Neoplasm, Neoplasms. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Valo Health and nference Announce Long-term Partnership to Accelerate Human-Centric Drug Discovery and Development</td><td>Discovery asset with PARP x PARP1 x PARP2 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr></tbody></table><p><strong>Shortlist interpretation.</strong> Priority one should receive the fastest outreach only after the returned owner and stage are reconfirmed. Lower-ranked rows preserve option value and may support a regional license, co-development collaboration, asset carve-out, structured option, research partnership or financing-linked agreement. Any mismatch among asset name, owner, indication and stage is itself a diligence signal that may reflect a transfer, dormant program, territory split or portfolio reprioritization.</p><p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><img src="https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/image_2ed6f2cf76.png" alt="PatSnap Life Sciences MCP workflow for Valo Health"></a></p><h2>Pipeline and evidence-package readout</h2><p>The organization pipeline fetch anchors asset identity, target, indication and development stage when those fields are returned. Reconcile them against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, subgroup results, safety narratives, manufacturing comparability, stability data, health-authority feedback and the sponsor’s integrated development plan.</p><p>Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across the company record, trial registries and regulatory sources. A stage label should be translated into a milestone map with dates, endpoints, decision gates and remaining cost. Where the MCP result is missing or ambiguous, do not fill the gap by assumption: make the refresh and reconciliation an explicit condition before valuation.</p><h2>Deal precedents and structure signals</h2><table><thead><tr><th>Date</th><th>Transaction</th><th>Status</th><th>Disclosed economics</th></tr></thead><tbody><tr><td>2025-11-20</td><td>Valo Health Announces Collaboration with Merck KGaA, Darmstadt, Germany to Discover and Develop Novel Treatments for Parkinson’s Disease and Related Disorders</td><td>Active</td><td>Not disclosed</td></tr><tr><td>2025-03-18</td><td>Valo Health and nference Announce Long-term Partnership to Accelerate Human-Centric Drug Discovery and Development</td><td>Active</td><td>Not disclosed</td></tr><tr><td>2025-01-08</td><td>Novo Nordisk Adds Obesity and Diabetes to AI Drug Research Pact With Flagship’s Valo Health</td><td>Active</td><td>Not disclosed</td></tr></tbody></table><p>Transaction precedents guide structure rather than mechanically determine price. Normalize every comparison for stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones, sublicensing, governance, termination and change-of-control provisions. Undisclosed economics can still reveal counterparties, strategic intent and preferred transaction form. A missing search result should trigger a broader licensor/licensee and asset-level search before negotiation.</p><h2>Financial capacity and partnering pressure</h2><ul><li><strong>Avalo Therapeutics, Inc. - 2023 Annual report</strong>: Avalo Therapeutics, Inc. - 2023 Annual report Overview The Company uses cash to primarily fund the ongoing development of our research and development pipeline assets and costs associated with its organizational infrastructure. As of December 31, 2023, Avalo had $7.4 million in cash and cash equivalents, representing a $5.8 million decrease compared to December 31, 2022. We raised approximately $46.2 million of net proceeds from equity financings during the year. We fully retired our original $35 million of debt with principal payments of $21.2 million in 2023, inclusive of the full payoff of the loan in September of 2023. We expect future cash used in operating activities to increase in 2024 as a result of acquiring AVTX-009 in March 2024 and our associated development plans. Cash Flows The following table summarizes our cash flows for the years ended December 31, 2023 and 2022: Year En</li><li><strong>Avalo Therapeutics, Inc. - 2021 Annual report</strong>: Avalo Therapeutics, Inc. - 2021 Annual report Overview Research and development expense for the year ended December 31, 2021 significantly increased as compared to the prior year, which was driven by the advancement of our maturing pipeline. Notably, we incurred significant expenses related to the clinical development of AVTX-002, which included increased drug manufacturing to support clinical trials. We also recognized a $10 million upfront license fee related to the expanded indication license agreement for AVTX-002 entered into with KKC during the year. In addition, there were moderate increases to program costs for AVTX-007, AVTX-006 and AVTX-803 as we progressed the therapies toward pivotal trials. There was also a moderate increase to general and administrative expense related to the infrastructure needed to support the Company’s expansion of its research and development efforts. S</li><li><strong>Verona Pharma plc - 2023 Annual report</strong>: Verona Pharma plc - 2023 Annual report Risks Related to Commercialization Net cash used in operating activities was $50.2 million in the year ended December 31, 2023 compared to $59.9 million during the year ended December 31, 2022, a decrease of $9.6 million. The decrease in cash used in operating activities was primarily due to the decrease in clinical trial and other development costs, partially offset by payments made throughout the twelve months ended December 31, 2023 related to Accounts payable and Accrued expenses balances included on the Consolidated Balance Sheet as of December 31, 2022. This was partially offset by the increase in people related costs and costs associated with the build out of information technology and commercial infrastructure in preparation for the planned commercial launch. Additionally, in the year ended December 31, 2022 we received payment of the 2021 R</li></ul><p>Translate financial signals into BD questions. Confirm unrestricted cash, quarterly operating use, committed trials, debt and royalty financing, covenant constraints, near-term milestone receipts, commercial investment and management’s minimum runway threshold. A well-capitalized company may prefer a premium strategic collaboration; a constrained company may prioritize non-dilutive funding, regional monetization, cost sharing or a staged option.</p><h2>Current-awareness events and outreach triggers</h2><p>The Current Awareness <code>news_search</code> call did not return a parseable recent-event record at the decision date. Refresh the search before outreach and reconcile press releases, trial updates, regulatory events, financing announcements, management changes and partnering disclosures. Do not interpret the missing return as absence of news.</p><p>The best outreach window often follows a data readout, regulatory interaction, financing, portfolio review, leadership change or new transaction. Build a trigger calendar and identify the person who owns the asset, the therapeutic-area BD lead, the regional commercial lead and alliance-management stakeholders. Outreach should cite one verified event and one specific contribution the prospective partner can make.</p><h2>IP and freedom-to-operate risk screen</h2><p>The IP review is a gating workstream, not a footnote. Request the full patent-family schedule, inventorship and assignment history, prosecution status, expected expiries, patent-term adjustment or extension assumptions, opposition and litigation history, third-party licenses, field and territory restrictions, royalties, reach-through clauses, government rights and material-transfer obligations. Map composition-of-matter, method-of-use, formulation, manufacturing, biomarker, combination, platform and delivery claims to the exact rights proposed in the deal.</p><p>Screen risk as medium by default when an asset and owner are returned but the patent package has not been reviewed; elevate it to high where ownership, stage or program status is not returned. A license must match patents, know-how, data, regulatory references, materials, manufacturing rights and sublicensing rights to the precise field and geography. Complete a claim-level patent and FTO review before exclusivity, valuation or term-sheet approval.</p><h2>Recommended deal structures</h2><ul><li><strong>Regional license:</strong> useful when development or commercial capabilities differ by territory; define data access, regulatory responsibilities, supply, transfer pricing and reversion rights.</li><li><strong>Co-development:</strong> appropriate when both parties contribute clinical, biomarker, regulatory or commercial capabilities; specify cost sharing, governance, global strategy and opt-out economics.</li><li><strong>Option-to-license:</strong> reduces uncertainty before a defined data event; specify option fee, exercise trigger, diligence standard, exclusivity period and pre-agreed economics.</li><li><strong>Research or platform collaboration:</strong> suitable when the value resides in discovery or delivery capability; define targets, ownership of foreground IP, publication, replacement rights and downstream options.</li><li><strong>Structured financing:</strong> may combine equity, milestone funding, royalties or territory monetization; test covenant, accounting, control and change-of-control implications.</li></ul><h2>Outreach rationale and first-contact plan</h2><ol><li><strong>Identify the decision owner.</strong> Map the asset team, corporate-development lead, therapeutic-area leadership, regional commercial lead and alliance-management stakeholders.</li><li><strong>Lead with one verifiable gap.</strong> Focus on territory, evidence, diagnostics, manufacturing, delivery, financing or combination strategy rather than a generic partnership request.</li><li><strong>Attach a concise evidence package.</strong> Include the returned stage, indication footprint, relevant transaction precedent, partner contribution, proposed work plan and decision gates.</li><li><strong>Offer a structure.</strong> Present one primary and one fallback structure with clear rights, funding, governance and diligence assumptions.</li><li><strong>Define the diligence sequence.</strong> Request data-room access, IP/FTO materials, CMC documents, safety data, regulatory correspondence, economics and encumbrances before exclusivity.</li></ol><h2>Decision memo</h2><p><strong>ADVANCE TARGETED OUTREACH, SUBJECT TO EVIDENCE REFRESH.</strong> Valo Health offers a credible screening case because the MCP workflow identifies either a returned pipeline opportunity or a concrete set of evidence gaps that can be tested rapidly. The first contact should be tailored to a named asset where available, quantify the partner’s contribution, acknowledge IP and execution risks and avoid using pipeline count as a proxy for value.</p><p><strong>Required next diligence:</strong> refresh all four MCP searches; fetch full deal records for economics and rights; reconcile the newest financial filing and public event disclosures; verify owner and license chain; obtain patent-family and FTO work; review CMC, safety and regulatory materials; and model risk-adjusted economics by indication, territory and transaction structure.</p><p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><img src="https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/image_dddd7a2c83.png" alt="Explore PatSnap MCP servers for Valo Health partnering intelligence"></a></p><p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><strong>Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.</strong></a></p><hr><p><strong>Data provenance:</strong> PatSnap Company & Deal Intelligence MCP (<code>organization_pipeline_fetch</code>, <code>drug_deal_search</code>, <code>financial_report_search</code>) and Current Awareness MCP (<code>news_search</code>); accessed 22 July 2026. Counts, ownership and statuses may change as records update.</p>